Glenmark

New Jersey: Glenmark Pharmaceuticals Inc., USA (Glenmark), has announced the launch of Axitinib Tablets, 1 mg and 5 mg. This product is an Authorized Generic version of INLYTA1 (axitinib) tablets.

According to IQVIA® sales data for the 12-month period ending September 2026, U.S. annual sales of INLYTA® Tablets were approximately $538.4 million*.

“The launch of Axitinib Tablets reinforces Glenmark’s commitment to expanding access to quality, affordable medicines for patients in the United States,” said Marc Kikuchi, President & Business Head, North America. By adding this important product to our portfolio, we continue to strengthen our focus on addressing the evolving needs of patients and healthcare providers.”

1INLYTA® is a registered trademark of Pfizer Inc.

*IQVIA® National Sales Perspectives: Retail & Non-Retail, September 2026

Glenmark Pharmaceuticals Ltd. is a global, research-led pharmaceutical company with a unique focus on innovation and accessibility. We pioneer transformative breakthrough therapies that aim to redefine treatment while expanding access to high-quality and affordable medicines for patients around the world. With 11 world-class manufacturing facilities across four continents, supported by six cutting-edge R&D centres, and a commercial footprint in 80+ countries, we deliver a diversified portfolio across branded, innovative, generics, and consumer health products, with a focus on respiratory, dermatology, and oncology. Scrip 100 positions Glenmark among the Top 100 biopharmaceutical companies globally by pharmaceutical sales for 2024.

Tags:    

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .